Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
- PMID: 23176083
- PMCID: PMC3674614
- DOI: 10.1186/ar4099
Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort
Abstract
Introduction: Clinical trials have demonstrated that treatment-to-target (T2T) is effective in achieving remission in early rheumatoid arthritis (RA). However, the concept of T2T has not been fully implemented yet and the question is whether a T2T strategy is feasible in daily clinical practice. The objective of the study was to evaluate the adherence to a T2T strategy aiming at remission (Disease Activity Score in 28 joints (DAS28) < 2.6) in early RA in daily practice. The recommendations regarding T2T included regular assessment of the DAS28 and advice regarding DAS28-driven treatment adjustments.
Methods: A medical chart review was performed among a random sample of 100 RA patients of the DREAM remission induction cohort. At all scheduled visits, it was determined whether the clinical decisions were compliant to the T2T recommendations.
Results: The 100 patients contributed to a total of 1,115 visits. The DAS28 was available in 97.9% (1,092/1,115) of the visits, of which the DAS28 was assessed at a frequency of at least every three months in 88.3% (964/1,092). Adherence to the treatment advice was observed in 69.3% (757/1,092) of the visits. In case of non-adherence when remission was present (19.5%, 108/553), most frequently medication was tapered off or discontinued when it should have been continued (7.2%, 40/553) or treatment was continued when it should have been tapered off or discontinued (6.2%, 34/553). In case of non-adherence when remission was absent (42.1%, 227/539), most frequently medication was not intensified when an intensification step should have been taken (34.9%, 188/539). The main reason for non-adherence was discordance between disease activity status according to the rheumatologist and DAS28.
Conclusions: The recommendations regarding T2T were successfully implemented and high adherence was observed. This demonstrates that a T2T strategy is feasible in RA in daily clinical practice.
Figures

Similar articles
-
The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.Arthritis Res Ther. 2019 Jul 5;21(1):164. doi: 10.1186/s13075-019-1937-4. Arthritis Res Ther. 2019. PMID: 31277720 Free PMC article.
-
Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.Arthritis Rheum. 2011 Oct;63(10):2865-72. doi: 10.1002/art.30494. Arthritis Rheum. 2011. PMID: 21647867
-
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.Arthritis Rheum. 2010 Jan;62(1):22-32. doi: 10.1002/art.27227. Arthritis Rheum. 2010. PMID: 20039405
-
[TNF targetting therapy for rheumatoid arthritis].Nihon Naika Gakkai Zasshi. 2006 Sep 10;95(9):1787-94. doi: 10.2169/naika.95.1787. Nihon Naika Gakkai Zasshi. 2006. PMID: 17037316 Review. Japanese. No abstract available.
-
Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.Reumatismo. 2009 Apr-Jun;61(2):107-17. doi: 10.4081/reumatismo.2009.107. Reumatismo. 2009. PMID: 19633797 Review.
Cited by
-
Long-term clinical, functional, and cost outcomes for early rheumatoid arthritis patients who did or did not achieve early remission in a real-world treat-to-target strategy.Clin Rheumatol. 2019 Oct;38(10):2727-2736. doi: 10.1007/s10067-019-04600-7. Epub 2019 Jun 3. Clin Rheumatol. 2019. PMID: 31161488
-
Barriers to treatment adjustment within a treat to target strategy in rheumatoid arthritis: a secondary analysis of the TRACTION trial.Rheumatology (Oxford). 2018 Nov 1;57(11):1933-1937. doi: 10.1093/rheumatology/key179. Rheumatology (Oxford). 2018. PMID: 29982720 Free PMC article. Clinical Trial.
-
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. Epub 2017 Jul 6. Ann Rheum Dis. 2018. PMID: 28684559 Free PMC article.
-
Rational therapy in RA: Issues in implementing a treat-to-target approach in RA.Nat Rev Rheumatol. 2013 Mar;9(3):137-8. doi: 10.1038/nrrheum.2013.18. Epub 2013 Feb 12. Nat Rev Rheumatol. 2013. PMID: 23399690 No abstract available.
-
Practice what you preach? An exploratory multilevel study on rheumatoid arthritis guideline adherence by rheumatologists.RMD Open. 2016 May 17;2(1):e000195. doi: 10.1136/rmdopen-2015-000195. eCollection 2016. RMD Open. 2016. PMID: 27252892 Free PMC article.
References
-
- Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, Gorter S, Knevel R, Nam J, Schoels M, Aletaha D, Buch M, Gossec L, Huizinga T, Bijlsma JW, Burmester G, Combe B, Cutolo M, Gabay C, Gomez-Reino J, Kouloumas M, Kvien TK, Martin-Mola E, McInnes I, Pavelka K, van Riel P, Scholte M, Scott DL, Sokka T, Valesini G. et al.EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;14:964–975. doi: 10.1136/ard.2009.126532. - DOI - PMC - PubMed
-
- Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, Blaauw AA, Bijlsma JW. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial) Ann Rheum Dis. 2007;14:1443–1449. doi: 10.1136/ard.2007.071092. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical